SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-028600
Filing Date
2023-06-16
Accepted
2023-06-16 16:07:38
Documents
13
Period of Report
2023-06-14
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kzr-20230614.htm   iXBRL 8-K 77061
2 EX-3.1 kzr-ex3_1.htm EX-3.1 20791
  Complete submission text file 0000950170-23-028600.txt   222637

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kzr-20230614_pre.xml EX-101.PRE 10244
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kzr-20230614.xsd EX-101.SCH 2493
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kzr-20230614_lab.xml EX-101.LAB 13895
7 EXTRACTED XBRL INSTANCE DOCUMENT kzr-20230614_htm.xml XML 4894
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Filer) CIK: 0001645666 (see all company filings)

IRS No.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38542 | Film No.: 231021099
SIC: 2834 Pharmaceutical Preparations